ToRsemide for pOstpartum HYpertension

Completed · Phase 2 · Has a placebo group

Conditions studied: Preeclampsia

In brief

Currently there is no intervention to prevent persistent postpartum hypertension in preeclamptic women. Physiologically, the use of a pharmacokinetically predictable loop-diuretic is a reasonable intervention to increase elimination of extra fluid accumulated secondary to preeclampsia.The purpose of this study is to assess if Torsemide reduces the incidence of persistent postpartum hypertension in preeclamptic women.

Key facts

Study ID

NCT02813551

Run by

The University of Texas Health Science Center, Houston

People needed

118

Starts

2016-08-01

Expected to finish

2017-09-09

Last updated by the study team

2019-04-10

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Postpartum women at ≥ 18 years of age
• Antepartum/intrapartum or within 24 hours postpartum diagnosis of either:
• Preeclampsia
• Preeclampsia with severe features
• Preeclampsia superimposed to chronic hypertension

You may not qualify if…

• Chronic hypertension without superimposed preeclampsia
• Gestational hypertension
• Urine output < 30 cc/h at time of randomization
• Heart failure or pulmonary edema
• Hypersensitivity to Torsemide or sulfonylureas
• Hypokalemia (serum potassium < 3 mEq/L)
• Preexisting diuretic use within 24 hours prior to randomization

Where it is running

• The University of Texas Health Science Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.